Adma Biologics (ADMA) Gross Profit (2011 - 2025)

Adma Biologics' Gross Profit history runs 13 years deep, the most recent figure standing at $88.8 million for Q4 2025.

• Quarterly Gross Profit rose 40.24% year-over-year to $88.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $292.8 million (up 33.35% YoY) and the FY2025 annual result came in at $292.8 million, up 33.35% from the prior year.
• Gross Profit was $88.8 million for Q4 2025 at Adma Biologics, up from $75.6 million in the prior quarter.
• Across five years, Gross Profit topped out at $88.8 million in Q4 2025 and bottomed at -$1.7 million in Q1 2021.
• A 5-year average of $31.9 million and a median of $20.7 million in 2023 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2021 — Gross Profit slumped 114.5% — and 2022, when it soared 2406.02%.
• Adma Biologics' Gross Profit stood at $3.5 million in 2021, then soared by 303.76% to $14.2 million in 2022, then jumped by 119.27% to $31.1 million in 2023, then jumped by 103.73% to $63.3 million in 2024, then surged by 40.24% to $88.8 million in 2025.
• Business Quant data shows ADMA's Gross Profit at $88.8 million in Q4 2025, $75.6 million in Q3 2025, and $67.2 million in Q2 2025.